Editorial Dept. Voz de la Diaspora
U.S – The United States drug regulatory body announced Thursday that it authorizes the Merck laboratory's anticovid pill for high-risk adults, a day after I gave the green light to a similar one from Pfizer.
The FDA Authorized Merck Drug For Adults With Early COVID-19 Symptoms Who Face The Highest Risks Of Hospitalization, including older adults and those with conditions such as obesity and heart disease. The United Kingdom was the first government to authorize the pill, early november.
The FDA does not authorize it for children under 18 years because it can affect the growth of bones and cartilage, nor is it recommended in pregnant women due to possible fetal harm. Doctors are the ones who decide whether the benefits outweigh the risks in individual cases.
The pill developed by Merck, known as MSD outside of the United States and Canada, is taken within five days after symptoms begin and has been shown to reduce a 30% hospitalizations and deaths from covid-19 among people at risk. Eight molnupiravir capsules are taken daily for five days, that is to say, a total of 40.
The FDA insisted in its statement that both Pfizer and Merck pills should be a complement to vaccines., instead of replacing them, because they continue to be the main tool in the fight against coronavirus.